What is the MSKCC nomogram?

The Memorial Sloan Kettering Cancer Center (MSKCC) nomogram is a validated statistical model that combines PSA level, Gleason score, and clinical T stage to estimate prostate cancer outcomes such as biochemical recurrence after surgery or radiation. It is widely used in urology research and clinical practice.

Is this tool a medical diagnosis?

No. This tool is for educational reference only. It illustrates how MSKCC risk-group criteria map to common inputs but does not account for all clinical variables, biopsy details, or individual patient factors. Always consult a qualified urologist or oncologist for medical decisions.

What PSA value should I enter?

Enter your most recent pre-treatment PSA level in ng/mL as reported by your lab. Values measured after treatment (post-operative PSA) are not used for initial risk stratification.

What is the Gleason score?

The Gleason score is a grading system for prostate cancer based on how abnormal the tumor cells look under a microscope. It is the sum of the two most common patterns found (each graded 1–5). Scores range from 6 (low-grade) to 10 (high-grade).

What are clinical T stages?

Clinical T stage describes how far the tumor has spread within or beyond the prostate: T1 means clinically inapparent (not palpable), T2 means palpable but confined to the prostate, T3 means tumor has extended beyond the prostate capsule, and T4 means the tumor invades adjacent structures.

What does the risk group mean?

Low risk generally indicates a favorable prognosis with a high chance of cure with local treatment. Intermediate risk suggests moderate concern for recurrence. High risk indicates a greater chance of disease spread and may require more aggressive or combined treatment approaches. Very high risk warrants specialized multidisciplinary evaluation.

MSKCC Prostate Cancer Prognosis Tool

Name: MSKCC Prostate Cancer Prognosis Tool
Availability: InStock
Author: Nham Vu

Enter PSA, Gleason score, and clinical stage to estimate prostate cancer risk grouping based on MSKCC nomogram criteria.

Clinical Inputs

Enter pre-treatment values from your pathology or lab report.

PSA Level (ng/mL)

Pre-treatment serum PSA in ng/mL.

Gleason Score (biopsy sum)

Clinical T Stage

Educational use only. This tool does not constitute medical advice. Risk groups follow published MSKCC/NCCN criteria but cannot replace individual clinical assessment.

Enter your clinical values and click
Estimate Risk Group to see results.

Summary

Enter PSA, Gleason score, and clinical stage to estimate prostate cancer risk grouping based on MSKCC nomogram criteria.

How it works

Enter your pre-treatment PSA level in ng/mL.
Select your Gleason score from the biopsy report.
Choose your clinical T stage (extent of tumor spread).
The tool maps your inputs to the MSKCC risk group criteria.
Review the estimated risk group and what it generally indicates.
Discuss results with your urologist or oncologist for clinical decisions.

Use cases

Understand where PSA, Gleason, and stage inputs place you on the MSKCC risk scale.
Prepare informed questions before a prostate cancer consultation.
Cross-reference a pathology report against published MSKCC criteria.
Educational review of how nomogram risk stratification works.
Support patient self-education before or after a diagnosis discussion.

Frequently Asked Questions

Last updated: 2026-07-24 · Reviewed by Nham Vu